Search results for " cancer stem cell"

showing 10 items of 71 documents

Colon Cancer Stem Cells: Promise of Targeted Therapy

2010

First developed for hematologic disorders, the concept of cancer stem cells (CSCs) was expanded to solid tumors, including colorectal cancer (CRC). The traditional model of colon carcinogenesis includes several steps that occur via mutational activation of oncogenes and inactivation of tumor suppressor genes. Intestinal epithelial cells exist for a shorter amount of time than that required to accumulate tumor-inducing genetic changes, so researchers have investigated the concept that CRC arises from the long-lived stem cells, rather than from the differentiated epithelial cells. Colon CSCs were originally identified through the expression of the CD133 glycoprotein using an antibody directed…

Cell SurvivalColonColorectal cancermedicine.medical_treatmentMetastasisTargeted therapyColon cancer stem cellsCancer stem cellBiomarkers TumormedicineAnimalsHumansHepatologybiologyCD44GastroenterologyLGR5Cell Differentiationmedicine.diseaseGene Expression Regulation NeoplasticCell Transformation NeoplasticDrug Resistance NeoplasmColonic NeoplasmsNeoplastic Stem CellsCancer researchbiology.proteinStem cellSignal TransductionAdult stem cell
researchProduct

Therapeutic implications of Cancer Initiating Cells.

2009

Background: Until few years ago, all neoplastic cells within a tumour were suggested to have tumorigenic capacity, but recent evidences hint to the possibility that such feature is confined to a subset of Cancer Initiating Cells (CICs), also called Cancer Stem Cells (CSCs). These cells are the reservoir of the heterogeneous populations of differentiated cancer cells constituting the tumour bulk. Mechanisms shared with somatic stem cells, such as quiescence, self-renewal ability, asymmetric division and multidrug resistance, allow to these cells to drive tumour growth and to evade conventional therapy. Objective: Here, we give a brief overview on the origin of CICs, the mechanisms involved i…

Clinical BiochemistryCellPopulationCell- and Tissue-Based TherapyApoptosisBiologymedicine.disease_causeMedical OncologyDisease-Free SurvivalMiceCancer stem cellAntigens CDNeoplasmsDrug DiscoverymedicineAnimalsHumansAC133 AntigenNeoplasm MetastasiseducationInterleukin 4GlycoproteinsPharmacologyeducation.field_of_studyCancermedicine.diseasemedicine.anatomical_structureCell Transformation NeoplasticDrug Resistance NeoplasmImmunologyCancer cellCancer researchNeoplastic Stem Cellscancer initiating cells cancer stem cells drug resistance IL-4CarcinogenesisPeptidesNeoplasm TransplantationAdult stem cellExpert opinion on biological therapy
researchProduct

TOWARDS COLORECTAL CANCER STEM CELLS TARGETING: INVESTIGATING GENETIC AND EPIGENETIC LANDSCAPE

2022

Colorectal cancer Cancer stem cells Epigenetic alterations Therapeutic strategies
researchProduct

Imaging to study solid tumour origin and progression: lessons from research and clinical oncology

2017

Biomedical imaging in recent decades has clarified our understanding of normal and pathological cellular processes in vivo. In particular, this approach recently provided insights into processes occurring at a molecular or genetic level rather than at the anatomical level. The evolution of this discipline by engineering have led to its integration into biomedical research to (1) increase sensitivity and resolution imaging and to (2) improve tissue and cell specificity. Currently, imaging approaches are used in three different biomedical areas: (a) identification of cellular processes in physiological and disease state; (b) in vivo single-cell imaging; and (c) identification of new prognosti…

Diagnostic Imaging0301 basic medicineOncologymedicine.medical_specialtyPathologyeducationImmunologyBiologyMedical OncologyMultimodal Imaging03 medical and health sciences0302 clinical medicineCancer stem cellNeoplasmsInternal medicinemedicineAnimalsHumansImmunology and AllergyMolecular Targeted TherapySolid tumourClinical OncologyResearchOptical ImagingCell BiologyImaging cell biology cancer stem cellsMolecular ImagingCell Transformation Neoplastic030104 developmental biology030220 oncology & carcinogenesisDisease ProgressionNeoplastic Stem Cells
researchProduct

Editorial: Stem Cells in Endocrine Tumors

2021

Endocrine Tumorcancer stem cells (CSCs)business.industryEndocrinology Diabetes and Metabolismendocrine tumorEMTRC648-665Diseases of the endocrine glands. Clinical endocrinologyCancer researchEmt ; Biomarker ; Cancer Stem Cells (cscs) ; Endocrine Tumor ; Tumor MetabolismEndocrine systemMedicineBiomarker (medicine)biomarkerendocrine tumours cancer stem cells metabolic reprogramming EMT.tumor metabolismStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessFrontiers in Endocrinology
researchProduct

p63 Isoforms Regulate Metabolism of Cancer Stem Cells

2014

p63 is an important regulator of epithelial development expressed in different variants containing (TA) or lacking (ΔN) the N-terminal transactivation domain. The different isoforms regulate stem-cell renewal and differentiation as well as cell senescence. Several studies indicate that p63 isoforms also play a role in cancer development; however, very little is known about the role played by p63 in regulating the cancer stem phenotype. Here we investigate the cellular signals regulated by TAp63 and ΔNp63 in a model of epithelial cancer stem cells. To this end, we used colon cancer stem cells, overexpressing either TAp63 or ΔNp63 isoforms, to carry out a proteomic study by chemical-labeling …

Gene isoformProteomicsProteomeRegulatorBiologyProteomicsBiochemistryTransactivationCancer stem cellmedicineHumansMetabolomicsProtein IsoformsProtein Interaction MapsSettore BIO/10 - BIOCHIMICAp63 colon cancer stem cells proteomics stable isotope dimethyl labeling glucose metabolismSettore BIO/12Tumor Suppressor ProteinsCancerGeneral Chemistrymedicine.diseasePhenotypePeptide FragmentsCell biologyIsotope LabelingNeoplastic Stem CellsStem cellSignal TransductionTranscription Factors
researchProduct

Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells

2014

Osteosarcoma is a highly metastatic tumor affecting adolescents, for which there is no second-line chemotherapy. As suggested for most tumors, its capability to overgrow is probably driven by cancer stem cells (CSCs), and finding new targets to kill CSCs may be critical for improving patient survival. TP53 is the most frequently mutated tumor suppressor gene in cancers and mutant p53 protein (mutp53) can acquire gain of function (GOF) strongly contributing to malignancy. Studies thus far have not shown p53-GOF in osteosarcoma. Here, we investigated TP53 gene status/role in 3AB-OS cells-a highly aggressive CSC line previously selected from human osteosarcoma MG63 cells-to evaluate its involv…

HistologyTumor suppressor genePhysiologyEndocrinology Diabetes and MetabolismApoptosisIn situ hybridizationBiologyTNF-Related Apoptosis-Inducing LigandCell MovementCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaBiomarkers TumormedicineHumansNeoplasm Invasiveness3AB-OS cells CSCs Cancer cell dedifferentiation Cancer stem cells FISH Fluorescent in situ hybridization GOF Gain of function Human osteosarcoma MMPs Matrix metalloproteinases Mutant p53 Mutant p53 gain of function Mutp53 OS OsteosarcomaClonogenic assayTumor Stem Cell AssayCell ProliferationMembrane Potential MitochondrialOsteosarcomaCancerReceptors Death DomainCell DedifferentiationCell cyclemedicine.diseaseMolecular biologyAmino Acid SubstitutionProto-Oncogene Proteins c-bcl-2Gene Knockdown TechniquesMutationNeoplastic Stem CellsCancer researchOsteosarcomaEctopic expressionTumor Suppressor Protein p53Bone
researchProduct

Human osteosarcoma 3AB-OS cancer stem cells is a model to study microRNA-29b-1 involvement in self-renewal and fate decisions of stem cells

2014

Human osteosarcoma 3AB-OS cancer stem cells microRNA-29b-1 self-renewal
researchProduct

IL-4-mediated drug resistance in colon cancer stem cells

2008

Cancer stem cells are defined as cells able to both extensively self-renew and differentiate into progenitors. Cancer stem cells are thus likely to be responsible for maintaining or spreading a cancer, and may be the most relevant targets for cancer therapy. The CD133 glycoprotein was recently described as a reliable cancer stem-like cell marker in colon carcinoma. CD133+ cells are both necessary and sufficient to initiate tumour growth in animal models. The CD133+ cell population and spheroid cultures contain cells expressing the stem cell marker Musashi-1 which is involved in maintenance of stem cell fate in several tissues and importantly, this expression is maintained in stem-like cells…

Induced stem cellsCancerStem cell factorAntineoplastic AgentsCell BiologyBiologymedicine.diseaseStem cell markercolon carcinoma cancer stem cells (CSCs) CD133 musashi-1 (Msi-1) interleukin-4 (IL-4) apoptosis tumor chemoresistanceCancer stem cellDrug Resistance NeoplasmImmunologyColonic NeoplasmsmedicineCancer researchNeoplastic Stem CellsAnimalsHumansInterleukin-4Stem cellProgenitor cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioMolecular BiologyDevelopmental BiologyAdult stem cellCell cycle (Georgetown, Tex.)
researchProduct

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health

2011

William H. Chappell 1 , Linda S. Steelman 1,2 , Jacquelyn M. Long 2 , Ruth C. Kempf 2 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Jorg Basecke 3 , Franca Stivala 4 , Marco Donia 4 , Paolo Fagone 4 , Graziella Malaponte 4 , Maria C. Mazzarino 4 , Ferdinando Nicoletti 4 , Massimo Libra 4 , Danijela Maksimovic-Ivanic 5 , Sanja Mijatovic 5 , Giuseppe Montalto 6 , Melchiorre Cervello 7 , Piotr Laidler 8 , Michele Milella 9 , Agostino Tafuri 10 , Antonio Bonati 11 , Camilla Evangelisti 12 , Lucio Cocco 12 , Alberto M. Martelli 12,13 , and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University 2 Department of Physics, Greenville, N…

MAPK/ERK pathwayAgingmedicine.medical_treatmentDrug ResistancerafPI3KTargeted therapycombination therapyPhosphatidylinositol 3-Kinases0302 clinical medicineTARGETED THERAPYCANCER STEM CELLSNeoplasmsCancer Stem CellsMedicineExtracellular Signal-Regulated MAP Kinases0303 health sciencesCombination TherapybiologyTOR Serine-Threonine KinasesMTORHuman health Ras inhibitors MEK ERKTargeted TherapyDiscovery and development of mTOR inhibitors3. Good healthDRUG RESISTANCECell Transformation NeoplasticOncology030220 oncology & carcinogenesismTORraf KinasesPremature agingMAP Kinase Signaling SystemReviewsSenescence03 medical and health sciencesCell Line TumorHumansPTENProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyMitogen-Activated Protein Kinase Kinasesbusiness.industryAKTAktagingPTEN PhosphohydrolaseRafTransplantationSENESCENCEImmunologyras Proteinsbiology.proteinCancer researchaging; akt; cancer stem cells; combination therapy; drug resistance; mtor; pi3k; raf; senescence; targeted therapybusinessProto-Oncogene Proteins c-akt
researchProduct